2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2392 Update of a Phase 1 study of LUCAR-G39D: an Allogeneic CD20/CD19 Dual-targeted CAR Gamma Delta T cells in Adults with Relapsed / Refractory B-cell non-Hodgkin lymphoma (NHL)

Jingwei Yu, Linlin Cao, MSc2, Lanfang Li3, Jing Ming4, Zhengzi Qian5, Dandan Fan6, Lihua Qiu7, Xianming Liu8, Jiayi Han9, Xianhuo Wang, PhD10, Shiyong Zhou11, Zheng Song12, Zhao Peiqi, MD13, Yuekun Qi, PhD14, Qing Dai15, Wang Zhang16, Yue Zhu17, Cong Feng18, Cheng Wang19, Da Xu20, Jing Wang21, Jin Liu22, Ying He23, Hongchen Zheng24, Qinghe Zhang25, Guowei Fang26, Liping Sun, PhD27, Dong Geng28, Yongxin Luo29, Yinrui Jiang, MD30, Qi Zhou31, Kaiyang Ding, MD32, Huilai Zhang, PhD33
1 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
2 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
3 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
4 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
5 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
6 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
7 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
8 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
9 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
10 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
11 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
12 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
13 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China
14 Legend Biotech Co, Nanjing, China
15 Legend Biotech Co, Nanjing, China
16 Legend Biotech Co, Nanjing, China
17 Legend Biotech Co, Nanjing, China
18 Legend Biotech Co, Nanjing, China
19 Legend Biotech Co, Nanjing, China
20 Legend Biotech Co, Nanjing, China
21 Legend Biotech Co, Nanjing, China
22 Legend Biotech Co, Nanjing, China
23 Legend Biotech Co, Nanjing, China
24 Legend Biotech Co, Nanjing, China
25 Legend Biotech Co, Nanjing, China
26 Legend Biotech USA Inc, Somerset, New Jersey, United States
27 Legend Biotech Co, Nanjing, China
28 Legend Biotech USA Inc, Somerset, New Jersey, United States
29 Legend Biotech Co, Nanjing, China
30 Legend Biotech Co, Nanjing, China
31 Legend Biotech Co, Nanjing, China
32 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
33 Department of Lymphoma / State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China

Introduction: Autologous CD19-targeted chimeric antigen receptor (CAR)-T cell therapies have demonstrated clinical benefit for patients with R/R B-NHL; however, many patients are unable to receive these potentially life-saving therapies due to aggressive disease progression, manufacturing constraints, or limited access. We previously reported experience in the first 16 enrolled patients from first-in-human study with LUCAR-G39D (ASH 2025, Abstract 704), an allogeneic CAR-γδ T cell therapy co-targeting CD19 and CD20, demonstrating early safety and preliminary activity in heavily pretreated patients. Here, we present updated results from the ongoing phase I trial (NCT06395870), with extended follow-up, alongside integrated correlative analyses to deepen the understanding of the antitumor mechanisms underlying CAR-γδ T cell therapy.

Methods: This multicenter phase I clinical trial evaluates the safety and preliminary efficacy of LUCAR-G39D in adults with R/R B-NHL. Key criteria included measurable disease, CD19/CD20 positivity, and ≥ 2 prior lines (or refractory to 1) of therapy. All patients received moderate conditioning therapy with fludarabine (30mg/m2) and cyclophosphamide (500mg/m2) per day for 3-4 days followed by a single infusion of LUCAR-G39D at dose level 1 (DL1):30×106 (30M), DL2:100M, DL3:200M, DL4:400M, DL5:600M, or DL6:800M CAR-T cells. Accelerated titration (30M only) followed by BOIN dose escalation was adopted. Patients who completed the 30-day DLT period or experienced a DLT during that window were considered DLT evaluable. Treatment-emergent adverse events were graded by CTCAE v5.0; immune effector cell-associated neurologic syndrome (ICANS) and cytokine release syndrome (CRS) were assessed per ASTCT criteria. Objective response rates (ORR) were evaluated per Lugano 2014 criteria. CAR-T cell pharmacokinetics (PK) were assessed by qPCR. Longitudinal single cell RNA-seq, plasma cytokine, flow cytometry and circulating tumor DNA (ctDNA) were combined with radiographic response to compare responders vs. non-responders.

Results: As of 3 Jun 2026, 22 patients were administrated with LUCAR-G39D across 30M (n=1), 100M (n=6), 200M (n=5), 400M (n=6), 600M (n=3), and 800M (n=1). Median follow-up was 11.8 months (range 0.4-21.2); Median age was 56 years and 59% were male. Thirteen (59%) patients had diffuse large B-cell lymphoma, 1 (5%) patient had primary mediastinal large B-cell lymphoma, and 8 (36%) had follicular lymphoma. 82% of patients had Ann Arbor stage III-IV. The median number of prior lines of therapy was 3 (range 1-7). No ICANS, SPM, or GvHD were observed; 1 DLT event occurred at 800M, manifesting as Grade 4 HLH which did not downgrade to Grade 2 within 7 days. CRS occurred in 59% of patients (median onset time: 2 days post-infusion; median duration: 6 days), with 14% Grade 3 events. The most common grade ≥3 adverse events were hematologic toxicities. PK expansion was detected in 86% (19/22) of patients for all dose levels. The median Cmax was 2284 copies/μg gDNA (range 59-298278), with a median Tmax occurred 6 days after infusion. At the cut-off date, ORR was 73% (16/22), and the CR rate was 41% (9/22). Median duration of response (DoR) was 19.3 months (95% CI, 4.8-NA). Among the 16 responders, 6 patients (38%) experienced disease relapse; 10 patients (63%) had an ongoing response. The 6-month and 12-months response rates were 71% (95% CI, 41-88%) and 63% (32 -83%), respectively. Median PFS was 7.4 months (95% CI, 5.8-NA), and the 6-month PFS rate was 56% (31%–75%). 15 of 16 patients (94%) with paired baseline and Day 90 ctDNA samples showed decreased ctDNA levels (median 100%; range 36%-100%), with Day 30 ctDNA showing 87% concordance with subsequent radiography responses. Deepening responses featured sustained cytotoxicity and immune-remodeling cytokine (e.g. GZMB, FLT3L) secretion, showed efficient B cell reduction, rising CD8+, enriched T-cell stemness and proliferation, fewer Tregs, reduced exhaustion with single-cell transcriptomic characterization.

Conclusions: With extended follow-up, LUCAR-G39D demonstrated durable and robust efficacy in heavily pretreated R/R B-NHL, with a median DoR of 19.3 months and 63% of responders maintaining ongoing responses at 12 months. Sustained cytotoxicity and host immune remodeling enhanced durable efficacy. This therapeutic strategy warrants further investigation.

Acknowledgements: This study was supported by Legend Biotech.

Jingwei Yu: No relevant conflicts of interest to declare.